Blood Activating and Stasis Removing Chinese Patent Medicine in Perioperative Period of Percutaneous Coronary Intervention for Myocardial Infarction: A Protocol for a Living Clinical Practice Guideline
Clinical and Public Health Guidelines · 2026-04 · 3 (2)
DOI: 10.1002/gin2.70068 ↗Kurz gefasst
Leitlinie in der Zeitschrift Clinical and Public Health Guidelines, online erschienen am 01.04.2026. Verfasst von Zumao Cao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Internal Medicine of Traditional Chinese Medicine of Ministry of Education and Beijing Beijing University of Chinese Medicine Beiji…. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Myocardial infarction (MI) remains a major global health burden, with percutaneous coronary intervention (PCI) as the primary revascularization strategy. However, complications such as no‐reflow, reperfusion injury and in‐stent restenosis persist, requiring adjunctive therapies. Traditional Chinese Medicine (TCM), especially blood‐activating and stasis‐resolving Chinese patent medicine (CPM), is increasingly used in MI management.
Objective
To develop a living clinical practice guideline for the perioperative use of CPMs in the perioperative period of PCI for MI, based on rigorous and transparent methodology.
Methods
The guideline followed the WHO Handbook for Guideline Development, methods for developing integrated Chinese–Western medicine guidelines, and the living guideline framework. It will be reported in accordance with the RIGHT‐TCM extension. Clinical questions and outcomes were framed, selected and rated through structured discussions with the Guideline Steering Committee and the Guideline Development Group. A systematic review and Bayesian network meta‐analysis will evaluate the efficacy and safety of CPM. The certainty of evidence will be assessed using the GRADE approach, and recommendations will be formulated via the Evidence‐to‐Decision framework, incorporating benefits, harms, evidence certainty, feasibility and costs. When new clinical studies are included and critical outcomes' combined effect demonstrates directional or magnitude changes, the consensus and guideline development groups will jointly decide on new updates.
Conclusion
By addressing key clinical uncertainties and leveraging real‐time evidence updates, the guideline aims to enhance patient outcomes and support clinicians in decision‐making. Trial Registration: Guideline Registration Number: PREPARE‐2024CN596
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Internal Medicine of Traditional Chinese Medicine of Ministry of Education and Beijing Beijing University of Chinese Medicine Beijing China.
- Dongzhimen Hospital Beijing University of Chinese Medicine Beijing China.
- Center for Evidence-Based and Translational Medicine Zhongnan Hospital of Wuhan University Wuhan China.
- Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical Sciences Beijing China.
- Institute of Information on Traditional Chinese Medicine China Academy of Chinese Medical Sciences Beijing China.
- Shenzhen Bao'an District Traditional Chinese Medicine Hospital Shenzhen China.
ORCID-Profile: Zumao Cao, Fengxia Lin, Yinghui Jin, Romina Brignardello-Petersen
Zitieren
APA
Cao, Z., Wang, Y., Zhang, X., Zhang, L., Zeng, Z., Lin, F., Wang, H., Huang, J., Zou, C., Bi, Z., Jin, Y., Shang, H., & Brignardello-Petersen, R. (2026). Blood Activating and Stasis Removing Chinese Patent Medicine in Perioperative Period of Percutaneous Coronary Intervention for Myocardial Infarction: A Protocol for a Living Clinical Practice Guideline. Clinical and Public Health Guidelines, 3(2). https://doi.org/10.1002/gin2.70068
Vancouver
Cao Z, Wang Y, Zhang X, Zhang L, Zeng Z, Lin F, et al. Blood Activating and Stasis Removing Chinese Patent Medicine in Perioperative Period of Percutaneous Coronary Intervention for Myocardial Infarction: A Protocol for a Living Clinical Practice Guideline. Clinical and Public Health Guidelines. 2026;3(2). doi:10.1002/gin2.70068
BibTeX
@article{Cao2026,
author = {Cao, Zumao and Wang, Yongbo and Zhang, Xiaoyu and Zhang, Lei and Zeng, Zhicong and Lin, Fengxia and Wang, Hairong and Huang, Jingyu and Zou, Chong and Bi, Zhengan and Jin, Yinghui and Shang, Hongcai and Brignardello-Petersen, Romina},
title = {Blood Activating and Stasis Removing Chinese Patent Medicine in Perioperative Period of Percutaneous Coronary Intervention for Myocardial Infarction: A Protocol for a Living Clinical Practice Guideline},
journal = {Clinical and Public Health Guidelines},
year = {2026},
volume = {3},
number = {2},
doi = {10.1002/gin2.70068}
}
EUVIMED